UK-based clinical trials imaging platform Qureight has successfully closed a $20 million Series B funding round led by Molten Ventures, alongside participation from existing investors including Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension Investment. The enterprise-grade healthcare technology company specializes in providing precision endpoints and data-driven analytics for complex lung and heart disease trials. Qureight plans to utilize the fresh capital to expand its commercial team, enhance its contract research organization (CRO) services, and build an advanced AI imaging laboratory housing its proprietary 3D chest imaging Foundation Model.
Also Read: Dassault Systèmes Accelerates Life Sciences AI Strategy with $1.8 Billion Acquisition of ArisGlobal
This technology expansion will allow Qureight to reduce development timelines and apply its quantitative analytics across new therapeutic targets such as asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity alongside its established lung fibrosis solutions. Highlighted by the market opportunity, “The global lung and heart clinical trials market is expected to grow to USD $27.5bn by 2030, with a CAGR of 6.9% over the next six years. We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials,” commented Dr Muhunthan Thillai, MD PhD, Co-founder and CEO, Qureight. Endorsing the platform’s market momentum, Dr Inga Deakin PhD, Partner, Molten Ventures, added: “Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation.”
